ABSTRACT
OBJECTIVE: To assess the performance of a non-invasive prenatal screening test (NIPT) for a panel of dominant single-gene disorders (SGD) with a combined population incidence of 1 in 600. METHODS: Cell-free fetal DNA isolated from maternal plasma samples accessioned from 14 April 2017 to 27 November 2019 was analyzed by next-generation sequencing, targeting 30 genes, to look for pathogenic or likely pathogenic variants implicated in 25 dominant conditions. The conditions included Noonan spectrum disorders, skeletal disorders, craniosynostosis syndromes, Cornelia de Lange syndrome, Alagille syndrome, tuberous sclerosis, epileptic encephalopathy, SYNGAP1-related intellectual disability, CHARGE syndrome, Sotos syndrome and Rett syndrome. NIPT-SGD was made available as a clinical service to women with a singleton pregnancy at ≥ 9 weeks' gestation, with testing on maternal and paternal genomic DNA to assist in interpretation. A minimum of 4.5% fetal fraction was required for test interpretation. Variants identified in the mother were deemed inconclusive with respect to fetal carrier status. Confirmatory prenatal or postnatal diagnostic testing was recommended for all screen-positive patients and follow-up information was requested. The screen-positive rates with respect to the clinical indication for testing were evaluated. RESULTS: A NIPT-SGD result was available for 2208 women, of which 125 (5.7%) were positive. Elevated test-positive rates were observed for referrals with a family history of a disorder on the panel (20/132 (15.2%)) or a primary indication of fetal long-bone abnormality (60/178 (33.7%)), fetal craniofacial abnormality (6/21 (28.6%)), fetal lymphatic abnormality (20/150 (13.3%)) or major fetal cardiac defect (4/31 (12.9%)). For paternal age ≥ 40 years as a sole risk factor, the test-positive rate was 2/912 (0.2%). Of the 125 positive cases, follow-up information was available for 67 (53.6%), with none classified as false-positive. No false-negative cases were identified. CONCLUSIONS: NIPT can assist in the early detection of a set of SGD, particularly when either abnormal ultrasound findings or a family history is present. Additional clinical studies are needed to evaluate the optimal design of the gene panel, define target populations and assess patient acceptability. NIPT-SGD offers a safe and early prenatal screening option. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Subject(s)
Cell-Free Nucleic Acids/blood , Genetic Diseases, Inborn/diagnosis , High-Throughput Nucleotide Sequencing , Noninvasive Prenatal Testing/methods , Adult , Female , Fetus/embryology , Genetic Diseases, Inborn/embryology , Gestational Age , Humans , PregnancyABSTRACT
Western Siberia is the region with little information on the prevalence of hepatitis C virus (HCV) infection, genotypic diversity of HCV isolates and risk factors. A molecular epidemiological survey was conducted to clarify these issues. Four groups of volunteers were included in a cross-sectional study (n = 500 in each group): health care workers; daycare patients from a hospital for drug users, daycare patients from an AIDS prevention and control center; and persons admitted to a local general practice clinic for any reason (outpatients). The anti-HCV IgG prevalence was 4.6% in health care workers, 48.0% in a narcological center, 35.8% in AIDS center, and 5.6% in outpatients. HCV RNA was found in 79.3%-86.3% of seropositives. A total of 388 HCV isolates were genotyped by direct sequencing and phylogenetic analysis of the 5'-UTR and NS5B regions of HCV genome. The genotypes distribution was: 1b--50.3%, 2a--4.4%, 2c--0.3%, 3a--44.8%. One isolate (0.3%) could not be typed unambiguously. This genotypic diversity is intermediate between that of European Russia and China. Genotype 1 prevailed in an older age group (75% among 51-60 years old), and genotype 3 was most prevalent in young people (51.4% in 16-20 years old). A statistically significant (P < 0.05) increase in risk was found in intravenous drug users (odds ratio (OR) = 77.5), unemployed persons (OR = 16.3), persons having >4 sexual partners during lifetime (OR = 4.3), and male homosexuals (OR = 6.6).
Subject(s)
Hepacivirus/classification , Hepacivirus/genetics , Hepatitis C/epidemiology , Molecular Epidemiology , Adolescent , Adult , Aged , Child , Female , Genotype , Hepacivirus/immunology , Hepacivirus/isolation & purification , Hepatitis C/virology , Hepatitis C Antibodies/blood , Humans , Male , Middle Aged , Prevalence , RNA, Viral/blood , Risk Factors , Siberia/epidemiologyABSTRACT
The occurrence of markers, genotypic variability of isolates and risk factors for viral hepatitis C (HCV) were studied in 4 groups of residents of the Novosibirsk region (altogether 2,000 persons). Anti-HCV IgG were detected within the range from 4.6% among medical personnel to 48% among the patients of the drug-abuse clinic. The detection rate of HCV RNA in seropositive samples varied from 79.3% to 86.3%. The determination of genotype was carried out for 388 isolates: 1b--50.3%, 2a--4.4%, 2c--0.3%, 3a--44.8%. The highest risk indices with respect to HCV among the residents of the region were linked with the drug use (OR=77.5; p<0.05) as well as with risky behavior and low social status. The elevated numbers of seropositive persons were detected among unemployed (OR=16.3), alcohol abusers (OR=3.9), persons having more than 4 sex partners in their lifetime (OR=4.3) and persons having homosexual contacts (OR=6.6). In some groups blood transfusions also played a definite role in the transmission of HCV. In the analysis, carried out separately for two different genotypes the intravenous use of drugs was perceptibly stronger linked with VHC of genotype 3 (OR=85.5) in comparison with HCV of genotype 1 (OR=49.3) and genotype 2 (OR=41.1). Genotype 1 prevailed in the older age group and genotype 3, among young people.
Subject(s)
Hepacivirus/isolation & purification , Hepatitis C/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Female , Hepacivirus/genetics , Hepatitis C/blood , Hepatitis C/transmission , Hepatitis C Antibodies/blood , Humans , Male , Middle Aged , RNA, Viral/blood , Risk Factors , Rural Population , Siberia/epidemiology , Socioeconomic Factors , Substance Abuse, Intravenous/blood , Substance Abuse, Intravenous/epidemiology , Substance Abuse, Intravenous/microbiologyABSTRACT
Biochemical changes in lymphocyte plasma membranes were studied 3 and 18 h after whole-body exposure of rats to neutrons and gamma-rays at doses from 2 to 6 Gy. It was shown that fast neutrons, with an average energy of 1.5-2.0 MeV, increased the rate of lipid peroxidation more markedly than gamma-rays did. In addition, there was an increase in the number of free aminogroups on the thymocyte surface. Dose- and time-dependent parameters of changes in the aminogroup content on the cellular surface were quantitatively different after the effect of radiation with different LET.
Subject(s)
Lymphocytes/radiation effects , Animals , Cell Membrane/metabolism , Cell Membrane/radiation effects , Gamma Rays , Lipid Peroxides/metabolism , Lipid Peroxides/radiation effects , Lymphocytes/metabolism , Male , Membrane Lipids/metabolism , Membrane Lipids/radiation effects , Neutrons , Octoxynol , Polyethylene Glycols/pharmacology , Pyridoxal Phosphate/metabolism , Rats , Relative Biological Effectiveness , Whole-Body IrradiationSubject(s)
Bone Marrow/radiation effects , DNA/biosynthesis , Thymus Gland/radiation effects , Animals , DNA/radiation effects , Gamma Rays , Male , Methylation , Rats , Time FactorsABSTRACT
During 60-day hypokinesia the hemopoietic system of rats developed important changes typical of the stress-state (atrophy of thymico-lymphatic system, lymphopenia and neutrophilosis) and hypokinesia per se (activation at the early stage and inhibition at the late stage of bone marrow erythropiesis, reduction of the rate of lympho- and myelopoiesis by the end of the experiment, emergence of pathologically changed megakaryocytes).